Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Humanistic burden and health-related quality of life

17 evidence topics · 16 sources

Literature review: impact of developmental and epileptic encephalopathies on caregivers